Press Release Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases 6 hours ago
Press Release Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) Aug 3